You are here

Article Text

Article menu

Download PDFPDF

Miscellaneous
Oral gefitinib produces symptomatic and radiological benefit in advanced NSCLC
Free
  1. A K Banerjee
  1. Specialist Registrar (Research), Molecular Oncology Group, University of Cambridge, UK; anindo@mrc-lmb.cam.ac.uk

https://doi.org/10.1136/thx.2003.la71

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    ▴ Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA2003;290:2149–58
    OpenUrlCrossRefPubMedWeb of Science

    Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is one of the new biological treatments for lung cancer. EGFR mediates cancer cell growth, proliferation, invasion, and metastasis and inhibits apoptosis.

    This was a multicentre trial of gefitinib in patients with symptomatic stage …

    View Full Text